KALV Stock Analysis: Buy, Sell, or Hold?
KALV - KalVista Pharmaceuticals, Inc. Common Stock
$26.73
0.01 (0.04%)
▲
5d:
+0.3%
30d:
+33.98%
90d:
+79.4%
HOLD
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: Mar 24, 2026
0d
Smart Money Distribution
None View Scanner →
Strength: 7.9/10
Get Alerted When KALV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: KALV is 7.7% above its trading range ($24.81). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: KALV is 7.7% above its trading range ($24.81). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: KALV is currently trading at $26.73, which is considered extended relative to its 30-day fair value range of $18.53 to $24.81.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is approaching resistance at $26.84. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KALV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.60 (+18.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is approaching resistance at $26.84. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KALV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.60 (+18.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$18.53 -
$24.81
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- BEARISH: Price extended above range (+7.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($31.60)
Trading Range Analysis
30-Day Trading Range
$18.53 -
$24.81
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.94
Resistance Level
$26.85
Current Trend
Strong Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.58
Wall Street Target
$31.60
(+18.2%)
Revenue Growth (YoY)
30.7%
Profit Margin
-223.2%
Share & Embed Analysis
Last updated: May 10, 2026 12:36 PM ET
Data refreshes hourly during market hours. Next update: 1:36 PM
Data refreshes hourly during market hours. Next update: 1:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Piekos
SELL
1862 shares
2026-04-17
Nicole Sweeny
SELL
1862 shares
2026-04-17
Paul K Audhya
SELL
2686 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 60 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 52 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
